InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,131.60
(
-0.23%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
84.27
(
-0.24%
)
Bitcoin
61,006.79
(
0.32%
)
Post# of 252389
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

pcrutch

Send PM Follow Ignore
Followers 69
Posts 2711
Boards Moderated 0
Alias Born 02/25/2010

pcrutch

Re: None

Wednesday, 02/29/2012 5:22:45 PM

Wednesday, February 29, 2012 5:22:45 PM

Post# of 252389
INCY: Two NEJM articles out on Jakafi (COMFORT I and II studies)

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
http://www.nejm.org/doi/full/10.1056/NEJMoa1110557

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
http://www.nejm.org/doi/full/10.1056/NEJMoa1110556
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up